PharmaCyte Biotech (PMCB) SEC Filings & 10K Form $1.81 -0.06 (-3.21%) (As of 10/31/2024 ET) Add Compare Share Share SEC Filings Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends Recent PharmaCyte Biotech SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView09/16/20247:47 PMPharmaCyte Biotech (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 08/13/20243:37 PMPharmaCyte Biotech (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 05/23/20243:40 PMPharmaCyte Biotech (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/01/20243:05 PMPharmaCyte Biotech (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 02/14/20242:38 PMAyrton Capital LLC (Filed by)PharmaCyte Biotech (Subject)Form SC 13G02/06/20248:56 AMINTRACOASTAL CAPITAL, LLC (Filed by)PharmaCyte Biotech (Subject)Form SC 13G/A12/15/20234:25 PMPharmaCyte Biotech (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 11/24/20233:00 PMPharmaCyte Biotech (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/22/20234:01 PMPharmaCyte Biotech (Issuer)Silverman Joshua (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/22/20234:01 PMPharmaCyte Biotech (Issuer)Trujillo Carlos (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/22/20234:02 PMPharmaCyte Biotech (Issuer)WALKER WAYNE REMELL (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/22/20234:02 PMPharmaCyte Biotech (Issuer)WEINSTEIN ROBERT (Reporting)Form 4Statement of changes in beneficial ownership of securities 11/15/20237:45 PMPharmaCyte Biotech (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/09/20234:25 PMPharmaCyte Biotech (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies Kronos Bio SEC Filings Precision BioSciences SEC Filings Immuneering SEC Filings CEL-SCI SEC Filings Barinthus Biotherapeutics SEC Filings Monopar Therapeutics SEC Filings Theratechnologies SEC Filings Actinium Pharmaceuticals SEC Filings VolitionRx SEC Filings Kezar Life Sciences SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NASDAQ:PMCB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
